表紙
市場調査レポート

アジア太平洋地域の胃腸治療薬市場:地域の高いアンメットニーズで、パイプライン生物製剤の大きな可能性

Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need

発行 GBI Research 商品コード 295789
出版日 ページ情報 英文
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
アジア太平洋地域の胃腸治療薬市場:地域の高いアンメットニーズで、パイプライン生物製剤の大きな可能性 Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need
出版日: 2014年01月31日 ページ情報: 英文
概要

アジア太平洋地域の胃腸治療薬市場(過敏性腸症候群、潰瘍性大腸炎、クローン病)は、2012年の5億6,400万米ドル規模から、2019年までに7億8,400万米ドルまで拡大し、CAGRで4.8%の成長が予測されています。この地域では、インドが急速な成長を遂げ、CAGRで7.7%の成長の見通し、次いで中国がCAGRで6.4%の成長を遂げると見られています。

当レポートでは、アジア太平洋地域の胃腸治療薬市場について調査分析し、インド、中国、日本、オーストラリアに焦点を当てて、市場の概要、上市製品、パイプライン分析、市場予測、最近の取引に関する情報などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 過敏性腸症候群
  • 潰瘍性大腸炎
  • クローン病

第3章 上市製品

  • 過敏性腸症候群
  • 潰瘍性大腸炎
  • クローン病
  • 主な上市製品
    • Amitiza
    • Humira
    • Remicade
    • Simponi
    • Cimzia
    • Tysabri

第4章 パイプライン分析

  • 過敏性腸症候群
    • パイプライン全体
    • パイプライン分析:分子タイプ別
    • パイプライン分析:作用機序別
  • 潰瘍性大腸炎のパイプライン
    • パイプライン全体
    • パイプライン分析:分子タイプ別
    • パイプライン分析:作用機序別
  • クローン病のパイプライン
    • パイプライン全体
    • パイプライン分析:分子タイプ別
    • パイプライン分析:作用機序別
  • パイプラインにおける有望な候補薬
    • GSK-1605786
    • MLN0002
    • EMD-61753

第5章 市場予測

  • アジア太平洋地域
  • オーストラリア
  • インド
  • 中国
  • 日本
  • 市場促進要因と障壁

第6章 取引と戦略的統合

  • 取引分析
  • 主な共同開発取引
  • 主なライセンス取引

第7章 付録

図表

目次
Product Code: GBIHC320MR

GBI Research, the leading business intelligence provider, has released its latest research, "Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need", which provides insights into three therapeutic indications in gastrointestinal disorders in Asia-Pacific (APAC) markets of India, China, Japan and Australia. The report provides an in-depth analysis of the therapeutic indications of gastrointestinal disorders, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn's Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.

Scope

  • Disease overview and treatment usage patterns
  • Market size and forecast for IBS, UC and CD in APAC market from 2012 to 2019
  • Major marketed products for the indications types covered
  • In-depth pipeline analysis for IBS, UC and CD
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements in the gastrointestinal therapeutics market

Reasons to buy

  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Abstract

India and China's Gastrointestinal Treatment Markets to Witness Impressive Growth by 2019, Amid Period of Global Decline, says GBI Research

The gastrointestinal (GI) therapeutics market for Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn's Disease (CD) in the Asia-Pacific (APAC) region will increase in value from $564m in 2012 to $784m by 2019, at a Compound Annual Growth Rate (CAGR) of 4.8%, according to a new report from business intelligence provider GBI Research.

The company's latest report* states that in the APAC region, comprising Australia, India, China and Japan, India will experience the fastest growth during the forecast period, with a higher CAGR of 7.7%. This will be followed by the Chinese market, which is expected to achieve a CAGR of 6.4%.

This increase will occur at a time when the global GI market value is anticipated to decline from $6.8 billion in 2012 to $6.6 billion by 2019, at a negative CAGR of 0.3%, due to major patent expiries.

Arti Singh, Analyst for GBI Research, says: "As the most populated countries in the world, China and India account for a large usage of these drugs. Indeed, one of the major reasons behind the market growth in these locations, besides upcoming product launches, is a high number of patients, which will ultimately boost the size of the overall region's GI market."

However, any further revenue increase will be hindered by various barriers, including low diagnosis rates, the patent expiry of major marketed drugs, such as Humira, and reduced prescription of branded medicine.

Singh continues: "In the APAC region, especially in China, most of the GI market consists of herbal and other traditional Chinese medicines, resulting in very low market penetration for branded medicines.

"There is also limited uptake of branded drugs in India, thanks to large prescriptions of generics, branded generics and herbal treatments instead, which will impede the region's GI market ability to achieve greater sales by 2019," the analyst concludes.

*Gastrointestinal Therapeutics in Asia-Pacific Markets to 2019 - Strong Potential for Pipeline Biologics on Account of High Regional Unmet Need

This report provides an in-depth analysis of the therapeutic indications of gastrointestinal disorders, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn's Disease (CD), in the Asia-Pacific markets of India, China, Japan and Australia. It provides an estimation of market size for 2012, along with market forecasts until 2019.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Gastrointestinal Therapeutics in Asia-Pacific Market - Introduction

  • 2.1. Irritable Bowel Syndrome
    • 2.1.1. Classification
    • 2.1.2. Symptoms
    • 2.1.3. Etiology
    • 2.1.4. Pathophysiology
    • 2.1.5. Diagnosis
    • 2.1.6. Epidemiology
    • 2.1.7. Prognosis
    • 2.1.8. Treatment Options
  • 2.2. Ulcerative Colitis
    • 2.2.1. Classification
    • 2.2.2. Symptoms
    • 2.2.3. Etiology
    • 2.2.4. Pathophysiology
    • 2.2.5. Diagnosis
    • 2.2.6. Epidemiology
    • 2.2.7. Prognosis
    • 2.2.8. Treatment Options
  • 2.3. Crohn's Disease
    • 2.3.1. Classification
    • 2.3.2. Symptoms
    • 2.3.3. Etiology
    • 2.3.4. Pathophysiology
    • 2.3.5. Diagnosis
    • 2.3.6. Epidemiology
    • 2.3.7. Prognosis
    • 2.3.8. Treatment Options

3. Gastrointestinal Therapeutics in Asia-Pacific Market - Marketed Products (Global)

  • 3.1. Irritable Bowel Syndrome
  • 3.2. Ulcerative Colitis
  • 3.3. Crohn's Disease
  • 3.4. Key Marketed Products
    • 3.4.1. Amitiza
    • 3.4.2. Humira
    • 3.4.3. Remicade
    • 3.4.4. Simponi
    • 3.4.5. Cimzia
    • 3.4.6. Tysabri

4. Gastrointestinal Therapeutics in Asia-Pacific Market - Pipeline Analysis

  • 4.1. Irritable Bowel Syndrome
    • 4.1.1. Overall Pipeline
    • 4.1.2. Pipeline Analysis by Molecule Type
    • 4.1.3. Pipeline Analysis by Mechanism of Action
  • 4.2. Ulcerative Colitis Pipeline
    • 4.2.1. Overall Pipeline
    • 4.2.2. Pipeline Analysis by Molecule Type
    • 4.2.3. Pipeline Analysis by Mechanism of Action
  • 4.3. Crohn's Disease Pipeline
    • 4.3.1. Overall Pipeline
    • 4.3.2. Pipeline Analysis by Molecule Type
    • 4.3.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Promising Drug Candidates in the Pipeline
    • 4.4.1. GSK-1605786
    • 4.4.2. MLN0002
    • 4.4.3. EMD-61753

5. Gastrointestinal Therapeutics in Asia-Pacific Market - Market Forecast to 2019

  • 5.1. Asia-Pacific Markets
    • 5.1.1. Treatment Usage Patterns
    • 5.1.2. Annual Cost of Therapy
    • 5.1.3. Market Size
  • 5.2. Australia
    • 5.2.1. Treatment Usage Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. India
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. China
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Gastrointestinal Therapeutics in Asia-Pacific Market - Deals and Strategic Consolidations (Global)

  • 6.1. Deals Analysis
  • 6.2. Major Co-Development Deals
    • 6.2.1. AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide
    • 6.2.2. Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies
    • 6.2.3. Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease
  • 6.3. Major Licensing Deals
    • 6.3.1. AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program
    • 6.3.2. Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin
    • 6.3.3. GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx

7. Gastrointestinal Therapeutics in Asia-Pacific Market - Appendix

  • 7.1. Market Definitions
  • 7.2. Abbreviations
  • 7.3. Sources
  • 7.4. All Pipeline Drugs by Phase
    • 7.4.1. Discovery
    • 7.4.2. Preclinical
    • 7.4.3. IND/CTA-filed
    • 7.4.4. Phase I
    • 7.4.5. Phase II
    • 7.4.6. Phase III
    • 7.4.7. Pre-Registration
    • 7.4.8. Undisclosed
  • 7.5. Market Forecasts to 2019
    • 7.5.1. Asia-Pacific Markets
    • 7.5.2. Australia
    • 7.5.3. India
    • 7.5.4. China
    • 7.5.5. Japan
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009
  • Table 2: Gastrointestinal Therapeutics Market, Treatment Recommendations for Irritable Bowel Syndrome, 2009
  • Table 3: Gastrointestinal Therapeutics Market, Classification of Ulcerative Colitis, 2004
  • Table 4: Gastrointestinal Therapeutics Market, Diagnosis of Ulcerative Colitis, 2007
  • Table 5: Gastrointestinal Therapeutics Market, Difference Between Ulcerative Colitis and Crohn's Disease, 2007
  • Table 6: Gastrointestinal Therapeutics Market, Treatment Options of Ulcerative Colitis, 2011
  • Table 7: Gastrointestinal Therapeutics Market, Classification of Crohn's Disease, 2013
  • Table 8: Gastrointestinal Therapeutics Market, Percentage of Patients Affected by Symptoms of Crohn's Disease (%), 2012
  • Table 9: Gastrointestinal Therapeutics Market, Treatment Options for Crohn's Disease, 2009
  • Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013
  • Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013
  • Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013
  • Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013
  • Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013
  • Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013
  • Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013
  • Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012
  • Table 18: Gastrointestinal Therapeutics Asia-Pacific Markets, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 19: Gastrointestinal Therapeutics Market, Asia-Pacific Markets, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 20: Gastrointestinal Therapeutics Market, Asia-Pacific Markets, Crohn's Disease, Market Forecast, 2012-2019
  • Table 21: Gastrointestinal Therapeutics Market, Australia, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 22: Gastrointestinal Therapeutics Market, Australia, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 23: Gastrointestinal Therapeutics Market, Australia, Crohn's Disease, Market Forecast, 2012-2019
  • Table 24: Gastrointestinal Therapeutics Market, India, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 25: Gastrointestinal Therapeutics Market, India, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 26: Gastrointestinal Therapeutics Market, India, Crohn's Disease, Market Forecast, 2012-2019
  • Table 27: Gastrointestinal Therapeutics Market, China, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 28: Gastrointestinal Therapeutics Market, China, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 29: Gastrointestinal Therapeutics Market, China, Crohn's Disease, Market Forecast, 2012-2019
  • Table 30: Gastrointestinal Therapeutics Market, Japan, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 31: Gastrointestinal Therapeutics Market, Japan, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 32: Gastrointestinal Therapeutics Market, Japan, Crohn's Disease, Market Forecast, 2012-2019

List of Figures

  • Figure 1: Gastrointestinal Therapeutics Market, Treatment Algorithm of Ulcerative Colitis, 2007
  • Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza ($m), 2006-2012
  • Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira ($bn), 2006-2012
  • Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade ($bn), 2006-2012
  • Figure 5: Gastrointestinal Therapeutics Market, Global, Sales of Simponi ($m), 2009-2012
  • Figure 6: Gastrointestinal Therapeutics Market, Global, Sales of Cimzia ($m), 2008-2012
  • Figure 7: Gastrointestinal Therapeutics Market, Global, Sales of Tysabri ($m), 2006-2012
  • Figure 8: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline, (%), 2013
  • Figure 9: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Molecule Type, 2013
  • Figure 10: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Mechanism of Action, 2012
  • Figure 11: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline, (%) 2013
  • Figure 12: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Molecule Type, 2013
  • Figure 13: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Mechanism of Action, 2013
  • Figure 14: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline, (%), 2013
  • Figure 15: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Molecule Type, 2013
  • Figure 16: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Mechanism of Action, 2013
  • Figure 17: Gastrointestinal Therapeutics Market, Asia-Pacific, Market Size, 2012-2019
  • Figure 18: Gastrointestinal Therapeutics Market, Australia, Market Size, 2012-2019
  • Figure 19: Gastrointestinal Therapeutics Market, India, Market Size, 2012-2019
  • Figure 20: Gastrointestinal Therapeutics Market, China, Market Size, 2012-2019
  • Figure 21: Gastrointestinal Therapeutics Market, Japan, Market Size, 2012-2019
  • Figure 22: Gastrointestinal Therapeutics Market, Global, Deals, 2006-2013
  • Figure 23: Gastrointestinal Therapeutics Market, Global, Co-Development Deals, 2006-2013
  • Figure 24: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006-2013
  • Figure 25: GBI Research Market Forecasting Model
Back to Top